LAVA Therapeutics N.V. stock is up 28.21% since 30 days ago. The next earnings date is Apr 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. LAVA-051 is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.